```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, represents a valuable research substance extensively employed in platelet research . This Fab fragment specifically targets the glycoprotein IIb/IIIa complex on thrombocytes , blocking platelet aggregation . As a result, it's commonly employed as a technique to explore the mechanisms underlying clotting and to assess the performance of anticoagulant therapies. Distribution is typically restricted to academic settings.
```
Abciximab Research: Utilizing The C7E3 Fragment and The 143653-53-6 Substance in Research Investigations
Ongoing studies into abciximab, a GPIIb/IIIa, frequently employs the monoclonal antigen C7E3 and the molecule identified as 143653-53-6. These reagents are essential for investigating abciximab's mode of function, determining its efficacy in experimental conditions, and understanding potential biomarkers of therapeutic success. Further exploration leveraging these specific reagents is likely to generate valuable insights for improving therapeutic strategies concerning cardiovascular conditions.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Exploring Scientific Possibilities with Abciximab 143653-53-6 via C7E3
Recent work demonstrate that Abciximab (identified as 143653-53-6) presents significant investigative promise, particularly when paired with a C7E3 construct. Preliminary findings suggested that this pairing might enhance patient outcomes in multiple heart-related settings. Further investigation is centered on defining the precise mode of action between the antiplatelet medication and C7E3, including assessment of blood clot cohesion and blood vessel protection.
- Ongoing investigation efforts seek to maximize dosing strategies.
- Preclinical approaches are were utilized to more assess such hypotheses.
- Patient trials will be necessary to completely determine therapeutic effectiveness.
```
Abciximab (C7E3) for Research: Specifications and Specifications (143653-53-6)
Researchers needing abciximab for laboratory investigations should meticulously assess quality and precise parameters . This product is typically supplied as a freeze-dried powder and comprehensive analytical documentation including assessment by mass spectrometry , potency assays, and endotoxin testing is available. Verify the manufacturer's documentation outlines required ranges for impurities and meets relevant quality control guidelines.
Pharmaceutical-Grade ReoPro Details & Availability
Acquiring laboratory-grade Abciximab, specifically referencing the antibody C7E3 and identified by the product number 143653-53-6, requires careful consideration of its origin . This agent is commonly utilized in cell-based investigations , particularly those related to platelet clumping and clotting . Existing vendors offer this material in varying quantities , typically ranging from g to substantial bulk amounts . Please advise reviewing the certificate of analysis check here to verify purity and appropriateness for your specific use . Additionally , ensure the shelf life date before purchasing to maintain maximum efficacy .
- Typical Purity: >95%
- Preservation Conditions: -20°C in suitable conditions
- Use : Platelet Aggregation Inhibition Studies